TED Ted Baker Plc

Tepnel Life Sciences PLC
05 September 2007



  Tepnel Life Sciences' pharmaceutical testing facility in Scotland officially
                         opened by Scottish Enterprise


5 September 2007: Tepnel Life Sciences (AIM: TED), the international Molecular
Diagnostics and Research Products and Services group, officially opened its new
#4million pharmaceutical testing facility based in Livingston, Scotland, today.


Scottish Enterprise CEO, Jack Perry, was present to open the state-of-the-art
laboratory, which will accommodate Tepnel's protein analysis and genomic testing
laboratories as well as the Company's existing pharmaceutical services business.


Operational activity began at the Livingston facility in July this year,
following a 12-month construction and validation period.


The facility's 14,000sq ft first phase will be occupied by 47 staff relocated
from Tepnel's Edinburgh, Glasgow and Welsh operations.  The second phase of
construction begins in September adding an additional 4000sq ft of custom
fit-out to house Tepnel's Molecular Services group which will provide
genotyping, whole genome amplification, sequencing and gene expression services.
The development of the second phase will be completed by the end of the year
and together, the two phases will house up to 20 new members of staff.


Tepnel plans to establish a clinical genotyping operation at Livingston while
continuing its successful development of specialised products and services in
high growth areas such as pharmacogenomics, new generations of vaccines and the
rapidly evolving therapeutic protein market.


Tepnel's Chief Executive Officer, Ben Matzilevich, said: "We are pleased to
officially open our facility at Livingston today.   We are making a substantial
investment in the area which we hope will benefit the region by creating new
employment opportunities and encouraging further investment and industry here."


Jack Perry, CEO at Scottish Enterprise said: "Scotland has a world class life
sciences sector that is further strengthened by the local commitment of
companies such as Tepnel Life Sciences.  The company's new state-of-the-art
facility will not only support local life sciences companies, it will work to
attract other global pharmaceutical companies to invest in Scotland."


Tepnel's new Livingston facility was part funded by Scottish Enterprise,
Edinburgh and Lothian.

                                     -Ends-


For further information:


Tepnel Life Sciences plc

Ben Matzilevich, CEO

Carol Smith

Tel: 0161 946 2200



Capital MS&L

Mary Clark or Catie Corcoran

Tel: +44 20 7307 5330


Seymour Pierce Limited

Mark Percy

Tel: +44 20 7107 8000


Notes to Editors:


About Tepnel Life Sciences plc


Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 195 employees.


Tepnel provides test kits, reagents and services to two highly synergistic
markets, these being Molecular Diagnostics and Biomedical Research.


The company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets.  Tepnel focuses on these opportunities
with internally developed products, patents, expertise and know-how as well as
strategic acquisitions, to develop a leadership position within these defined
market segments.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRASSUSULSWSEFU

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024